Skip to main content
. 2015 Oct 12;6(35):38270–38282. doi: 10.18632/oncotarget.5681

Figure 4. Survival analysis of miR-15a in newly diagnosed MM patients with thalidomide-based or bortezomib-based therapy.

Figure 4

A–B. In Arm A (thalidomide-based therapy), the patients with low miR-15a expression had inferior PFS (P = 0.046) and OS (P = 0.016). C–D. In Arm B (bortezomib-based therapy), the patients with low miR-15a expression also showed inferior PFS (P = 0.003) and OS (P = 0.002), suggesting that bortezomib-based therapy could not improve the poor survival of patients with low miR-15a expression.